Analyst Price Targets — DMAC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 7, 2024 9:07 am | Bill Chappell | Truist Financial | $10.00 | $4.42 | Benzinga | This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday |
| October 7, 2024 6:05 am | Matthew Caufield | H.C. Wainwright | $7.00 | $4.36 | TheFly | DiaMedica Therapeutics initiated with a Buy at H.C. Wainwright |
| March 21, 2024 9:10 am | Alex Nowak | Craig-Hallum | $8.00 | $2.69 | StreetInsider | DiaMedica Therapeutics Inc. (DMAC) PT Lowered to $8 at Craig-Hallum |
Latest News for DMAC
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS), today provided a business update and reported financial results for the year ended December 31, 2025. Management will host a conference call on Tuesday, March 31, 2026, at…
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) will release earnings for its fourth quarter after the closing bell on Monday, March 30.
Shares of DiaMedica Therapeutics, Inc. (NASDAQ: DMAC - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its full-year 2025 financial results will be released after the markets close on Monday, March 30th. DiaMedica will host a live conference call on Tuesday, March 31st…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DMAC.
U.S. House Trading
No House trades found for DMAC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.